User menu

Accès à distance ? S'identifier sur le proxy UCLouvain

Association of reduced relative dose intensity and survival in lymphoma patients receiving CHOP-21 chemotherapy.

Primary tabs

Pettengell, R Schwenkglenks, M Bosly, André [UCL]
Document type Article de périodique (Journal article)
Access type Accès restreint
Publication date 2008
Language Anglais
Journal information "Annals of Hematology" - Vol. 87, no.5, p. 429-30 (2008)
Peer reviewed yes
Publisher Springer ((Germany) Heidelberg)
issn 0939-5555
e-issn 1432-0584
Publication status Publié
Affiliation UCL - (MGD) Service d'hématologie
MESH Subject Adult ; Kaplan-Meier Estimate ; Lymphoma, Non-Hodgkin ; Medical Audit ; Middle Aged ; Prednisone ; Retrospective Studies ; Vincristine ; Aged ; Antineoplastic Combined Chemotherapy Protocols ; Belgium ; Cyclophosphamide ; Dose-Response Relationship, Drug ; Doxorubicin ; Great Britain ; Humans
Links
  1. Aapro MS, Cameron DA, Pettengell R, Bohlius J, Crawford J, Ellis M, Kearney N, Lyman GH, Tjan-Heijnen VC, Walewski J, Weber DC, Zielinski C (2006) EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours. Eur J Cancer 42:2433–2453
  2. Bosly A, Bron D, Van Hoof A, De Bock R, Berneman Z, Ferrant A, Kaufman L, Dauwe M, Verhoef G; for the Lymphoma Dose Project: a National Study (2008) Achievement of optimal average relative dose intensity and correlation with survival in diffuse large B-cell lymphoma patients treated with CHOP. Ann Hematol 87:277–283
  3. Marangolo M, Bengala C, Conte PF, Danova M, Pronzato P, Rosti G, Sagrada P (2006) Dose and outcome: the hurdle of neutropenia. Oncol Rep 16:233–248
  4. Pettengell R, Bosly A, Bron D, Schwenkglenks M, Johnson P, Van Hoof A, Hancock B, De Brock R, Pagliuca A, Berneman Z, Thomas R, Ferrant A, Joyner M, Dauwe M, Verhoef G, Hoskin P (2006) Association of reduced relative dose intensity and survival in lymphoma patients receiving CHOP-21 chemotherapy. Haematologica/Hematol J 91:69 (Abs 0185)
  5. Pfreundschuh M, Trumper L, Kloess M, Schmits R, Feller AC, Rube C, Rudolph C, Reiser M, Hossfeld DK, Eimermacher H, Hasenclever D, Schmitz N, Loeffler M, The German High-Grade Non-Hodgkin's Lymphoma Study G (2004) Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL. Blood 104:634–641
  6. Pfreundschuh M, Trumper L, Kloess M, Schmits R, Feller AC, Rudolph C, Reiser M, Hossfeld DK, Metzner B, Hasenclever D, Schmitz N, Glass B, Rube C, Loeffler M, The German High-Grade Non-Hodgkin's Lymphoma Study G (2004) Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL. Blood 104:626–633
Bibliographic reference Pettengell, R ; Schwenkglenks, M ; Bosly, André. Association of reduced relative dose intensity and survival in lymphoma patients receiving CHOP-21 chemotherapy.. In: Annals of Hematology, Vol. 87, no.5, p. 429-30 (2008)
Permanent URL http://hdl.handle.net/2078.1/124019